GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Olema Pharmaceuticals inc (NAS:OLMA) » Definitions » Goodwill

OLMA (Olema Pharmaceuticals) Goodwill : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Olema Pharmaceuticals Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Olema Pharmaceuticals's goodwill for the quarter that ended in Dec. 2024 was $0.00 Mil.


Olema Pharmaceuticals Goodwill Historical Data

The historical data trend for Olema Pharmaceuticals's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olema Pharmaceuticals Goodwill Chart

Olema Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill
Get a 7-Day Free Trial - - - - -

Olema Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Olema Pharmaceuticals Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Olema Pharmaceuticals  (NAS:OLMA) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Olema Pharmaceuticals's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (A: Dec. 2024 )=Goodwill/Total Assets
=0/450.979
=

Olema Pharmaceuticals's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=0/450.979
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Olema Pharmaceuticals Goodwill Related Terms

Thank you for viewing the detailed overview of Olema Pharmaceuticals's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Olema Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
780 Brannan Street, San Francisco, CA, USA, 94103
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Executives
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kovacs Shane William Charles officer: Ch. Operating & Financial Off. PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Naseem Zojwalla officer: Chief Medical Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Cyrus Harmon director, officer: Chief Technology Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Sean Bohen director, officer: President and CEO C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
David C. Myles officer: Chief Development Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Paradigm Biocapital Advisors Lp 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10017
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Senai Asefaw 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Paradigm Biocapital International Fund Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Paradigm Biocapital Advisors Gp Llc 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Kinney Horn officer: Chief Business Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Yi Larson director C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116